Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 35Carcinoma, Hepatocellular 17Neoplasm Metastasis 15Prostatic Neoplasms 13Neoplasms 9Neuroendocrine Tumors 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 6Brain Neoplasms 6Sarcoma, Ewing 5Sarcoma 5Osteosarcoma 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Transitional Cell 5Recurrence 4Pancreatic Neoplasms 4Multiple Myeloma 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Pheochromocytoma 2Paraganglioma 2Neurofibroma, Plexiform 2Melanoma 2

Interventions

Nivolumab 11Specimen Handling 8Ipilimumab 7pembrolizumab 5CTLA-4 Antigen 5cabozantinib 4Magnetic Resonance Spectroscopy 4Biopsy 4Radiosurgery 3Axitinib 3pazopanib 2Sunitinib 2Everolimus 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1lenvatinib 1belzutifan 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Nephrectomy 1Molecular Imaging 1Metastasectomy 1Inulin 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Clear-cell metastatic renal cell carcinoma × cabozantinib × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT05361720 2026-04-27

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
54 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

City of Hope Medical Center

Phase 1 Active not recruiting
31 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡